期刊
DIGESTIVE DISEASES AND SCIENCES
卷 60, 期 5, 页码 1433-1439出版社
SPRINGER
DOI: 10.1007/s10620-014-3495-6
关键词
Wilson disease; Treatment; Trientine; Adherence
资金
- Royal College of Physicians, London Sheila Sherlock Travel Fellowship in Hepatology
- Surrey and Sussex National Institute for Health and Research (NIHR)
- Aton and Valeant Pharmaceuticals
Background Wilson disease requires lifelong therapy, currently given daily in multiple divided dosages. Aim To prospectively evaluate once-daily trientine as therapy for Wilson disease. Methods Study group: eight patients (seven males) aged 22-71 years with stable Wilson disease treated from 4 to 50 years. Patients were monitored for 3 months then for 12 months on a single daily dose of trientine (15 mg/kg). Results All patients remained clinically well. ALT and AST fluctuated in some, but none required treatment stoppages or side effects. Liver synthetic function was unchanged. Mean 24-h urine copper and zinc excretions at end of treatment were 313.4 +/- 191.7 and 2,214 +/- 1,346 mu g, respectively. Conclusions Once-daily trientine should be explored further for possible maintenance therapy for WD. Single daily dose may improve adherence to therapy. Larger trials and longer-term follow-up will establish the safety and treatment efficacy of this once-daily treatment regimen for WD (registration: NCT01472874).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据